Gossamer Bio, Inc. 8-K

What Happened

• Gossamer Bio (GOSS) filed an 8-K on May 18, 2026 announcing a proposed Exchange Offer for its existing convertible notes and a Transaction Support Agreement with holders representing ~75.2% of those notes who agreed to tender and consent. The company also released its financial results for the quarter ended March 31, 2026 (press release attached) and disclosed confirmation of an in‑person Pre‑NDA Type B meeting with the FDA scheduled for mid‑June 2026 to discuss a potential NDA for seralutinib.
• The Transaction Support Agreement sets conditions and timelines for the Exchange Offer (including an Early Tender/Consent requirement and a Minimum Participation threshold of holders representing at least 98% of the existing notes, subject to limited waiver). Supporting noteholders also executed voting agreements to vote the New Shares received in the Exchange Offer in favor of the company’s Stockholder Proposals at a Special Meeting.
• Separately, the company amended and restated its 2019 Incentive Award Plan (the “Restated Plan”) effective May 18, 2026 (subject to closing of the Exchange Offer and stockholder approval) to increase the share reserve — estimated at about 77 million additional shares (assuming 100% participation) — and to add an annual evergreen increase through 2036.

Key Details

• Supporting Noteholders represent ~75.2% of the aggregate principal amount of the Existing Convertible Notes and agreed to tender and consent by the Early Tender Date.
• Minimum Participation required to close the Exchange Offer: holders of at least 98% of aggregate principal amount of the Existing Convertible Notes (waivable only by the company and Required Supporting Noteholders).
• Restated Plan: existing reserved shares = 69,238,008; proposed increase equals 10% of Post‑Transaction Fully‑Diluted Shares Outstanding (estimated ≈77M shares if 100% participate) plus annual increases (up to 5% of fully‑diluted shares each Jan 1 through 2036). If the Exchange Offer or stockholder approval does not occur, the increased reserve and any awards from it will be forfeited.
• Clinical/regulatory update: FDA Pre‑NDA Type B meeting confirmed for mid‑June 2026; company expects to submit an NDA for seralutinib in Sept 2026 (if meeting outcomes support filing) with potential FDA approval eligibility in Q3 2027. PROSERA CT FRI substudy (n=162) reported multiple exploratory imaging signals with nominal p‑values (e.g., arterial p=0.0200; venous volume p=0.0155; fibrosis p≈0.025–0.026) and correlations with clinical outcomes.

Why It Matters

• Debt restructuring and governance: The Transaction Support Agreement and Exchange Offer, backed by holders of ~75% of the notes, aim to replace existing convertible notes with new securities and stock; the 98% minimum participation requirement and voting agreements could materially affect creditor treatment and future control matters tied to the Stockholder Proposals.
• Potential dilution: The Restated Plan would substantially increase the pool of shares available for employee and other equity awards (estimated ~77M additional shares assuming full participation), which could dilute existing shareholders if the plan and Exchange Offer close and awards are granted.
• Clinical and timeline implications: Confirmation of a mid‑June Type B Pre‑NDA meeting and an expected Sept 2026 NDA submission for seralutinib are material near‑term milestones — acceptance could lead to potential approval timing in Q3 2027 and trigger pre‑launch activities. The exploratory imaging findings reported from PROSERA provide structural/biologic data the company intends to use in regulatory discussions.
• Financials: The company issued Q1 2026 results (press release attached) — investors should review that release for updated revenue, cash, and operating results, as the 8‑K itself does not disclose numeric financials beyond referencing the press release.

Keywords: Exchange Offer, Transaction Support Agreement, convertible notes, dilution, equity plan, restated incentive plan, seralutinib, FDA Pre‑NDA Type B, PROSERA, Q1 2026 results.